Compass Pathways — Third Quarter 2026 Earnings Summary

Compass Pathways is nearing the completion of its final New Drug Application submission for COMP360, with a planned filing within the next two weeks and a target launch in the first half of 2027 pending FDA approval. Recent data from Phase 3 trials and a 52-week open-label study demonstrate the treatment's rapid onset, durability, and safety profile for patients with treatment-resistant depression, potentially establishing a new standard of care. The company reported a net loss of $9.8 million for the third quarter of 2026, driven primarily by non-cash fair value adjustments on warrants, while maintaining a strong cash position of $444 million to fund operations through 2028. Additionally, Compass is advancing a late-stage clinical trial for post-traumatic stress disorder and has established a commercial team to support the anticipated market entry.